Compare Aeson Therapeutics vs Anza Therapeutics
Customers evaluate the quality of Aeson Therapeutics's products using the following success metrics.
Overview
Dehydroepiandrosterone (DHEA) may have therapeutic uses against cardiovascular disease, immune disorders, cancer and other diseases, but the hormone is a precursor of androgens and estrogens and can cause undesirable side effects. RCT formed Aeson Therapeutics to develop fluasterone, a synthetic steroid that may be more effective than DHEA without the adverse side effects. Fluasterone development targets include treatment of lipid disorders, inflammatory diseases and as a cancer chemoprevention agent. RCT and other investors provided funding for Aeson's initial development. Hollis-Eden Pharmaceuticals (NASDAQ:HEPH) in San Diego acquired Aeson in May 2006
Anza Therapeutics is based in United States
Anza Therapeutics is developing active immunotherapies for the treatment of infectious diseases and cancer. Anza's therapeutic agents are based on its proprietary live-attenuated and Killed But Metabolically Active (KBMA) Listeria platforms which can be engineered to express antigens specific to the disease being treated.
Demo Video
Leadership
Chad W. Souvignier (President)
David Cook (President)
Investors
Hollis-Eden Pharmaceuticals and Research Corporation Technologies
Sofinnova Partners and Kleiner Perkins Caufield & Byers
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because Aeson Therapeutics has not claimed their profile.
Work for Aeson Therapeutics? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Aeson Therapeutics?
Claim your profile now.
Information not available because Anza Therapeutics has not claimed their profile.
Work for Anza Therapeutics? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Anza Therapeutics?
Claim your profile now.